Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director | August 14, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sagimet Biosciences Inc.
Report date August 14, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Common StockSEC Table I · non-derivative | Direct | 62,161 |
Ending reported balance
After 2026-08-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-14 · Exercise / conversion · Acquired 326,618 · Balance 388,779 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. Row 2 · 2026-08-14 · Exercise / conversion · Acquired 24,369 · Balance 413,148 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. Row 3 · 2026-08-14 · Sale · Disposed 350,987 · Balance 62,161 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 31,455 |
Reported balance
After 2026-08-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-14 · Exercise / conversion · Disposed 326,618 · Balance 31,455 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F3: This option is fully vested and exercisable as of the date hereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-04-27 | Direct | 11,608 |
Reported balance
After 2026-08-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-14 · Exercise / conversion · Disposed 24,369 · Balance 11,608 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F3: This option is fully vested and exercisable as of the date hereof. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: This option is fully vested and exercisable as of the date hereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2026 Filed Aug 17, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,369 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001193125-26-354018 · ownership.xml · derivative · entry 5 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,608 Underlying: Series A Common Stock · 24,369 shares Expires 2029-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 326,618 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001193125-26-354018 · ownership.xml · derivative · entry 4 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,455 Underlying: Series A Common Stock · 326,618 shares Expires 2029-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 350,987 | $10.23 | $3,591,579.77 |
DisclosureSEC source: 0001193125-26-354018 · ownership.xml · nonDerivative · entry 3 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,161 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionSeries A Common Stock | 24,369 | $6.36 | $154,986.84 |
DisclosureSEC source: 0001193125-26-354018 · ownership.xml · nonDerivative · entry 2 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 413,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionSeries A Common Stock | 326,618 | $6.36 | $2,077,290.48 |
DisclosureSEC source: 0001193125-26-354018 · ownership.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 388,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 23:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,455 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001193125-26-347407 · ownership.xml · derivative · entry 5 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,977 Underlying: Series A Common Stock · 10,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F3 · derivative.expiration_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 23:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,751 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001193125-26-347407 · ownership.xml · derivative · entry 4 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 358,073 Underlying: Series A Common Stock · 9,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F3 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. F3 · derivative.expiration_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 23:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 20,206 | $9.95 | $201,146.69 |
DisclosureSEC source: 0001193125-26-347407 · ownership.xml · nonDerivative · entry 3 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,161 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.95 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 23:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionSeries A Common Stock | 10,455 | $6.36 | $66,493.80 |
DisclosureSEC source: 0001193125-26-347407 · ownership.xml · nonDerivative · entry 2 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 23:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionSeries A Common Stock | 9,751 | $6.36 | $62,016.36 |
DisclosureSEC source: 0001193125-26-347407 · ownership.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 18,844 | $7.46 | $140,529.13 |
DisclosureSEC source: 0001193125-26-312386 · ownership.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,161 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.17 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:20 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001104659-26-074045 · tm2617570-2_4seq1.xml · derivative · entry 1 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,567 Underlying: Series A Common Stock · 39,567 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 20, 2025 Filed Nov 21, 2025 23:13 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 37,688 | $7.69 | $289,979.01 |
DisclosureSEC source: 0001104659-25-115071 · tm2531988-1_4seq1.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,005 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.27 to $8.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 21:40 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 32,250 | $0.00 Strike: $5.33 | $0.00 |
DisclosureSEC source: 0001104659-25-058223 · tm2517621-4_4seq1.xml · derivative · entry 1 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,250 Underlying: Series A Common Stock · 32,250 shares Expires 2035-06-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 23,625 | $3.17 | $74,829.83 |
DisclosureSEC source: 0001104659-24-082630 · tm2420121-1_4seq1.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director · Executive Chairman 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,693 F1 · kind: These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.07 to $3.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 14,062 | $3.10 | $43,604.86 |
DisclosureSEC source: 0001104659-24-081887 · tm2420000-1_4.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,318 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:22 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 150,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-120374 · tm2331048-2_4seq1.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,380 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 20:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,630 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001104659-23-099310 · tm2325723-1_4seq1.xml · derivative · entry 2 Kemble George · CIK 0001858176 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Series A Common Stock · 5,630 shares Expires 2023-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| September 07, 2023 Filed Sep 8, 2023 20:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Exercise / conversionSeries A Common Stock | 5,630 | $0.79 | $4,447.70 |
DisclosureSEC source: 0001104659-23-099310 · tm2325723-1_4seq1.xml · nonDerivative · entry 1 Kemble George · CIK 0001858176 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 21,173 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 16 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,173 Underlying: Series A Common Stock · 21,173 shares Expires 2032-10-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F4 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,173 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 15 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,173 shares Expires 2032-10-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F4 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 526,332 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 14 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,332 Underlying: Series A Common Stock · 526,332 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 526,332 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 13 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 526,332 shares Expires 2031-01-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 46,432 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 12 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,432 Underlying: Series A Common Stock · 46,432 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,432 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 11 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,432 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 367,824 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 10 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 367,824 Underlying: Series A Common Stock · 367,824 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 367,824 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 9 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 367,824 shares Expires 2029-04-27 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 26,352 | $0.00 Strike: $19.87 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 8 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,352 Underlying: Series A Common Stock · 26,352 shares Expires 2025-10-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,352 | $0.00 Strike: $19.87 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 7 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,352 shares Expires 2025-10-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 7,147 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 6 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,147 Underlying: Series A Common Stock · 7,147 shares Expires 2024-12-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,147 | $0.00 Strike: $23.05 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 5 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,147 shares Expires 2024-12-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 3,179 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 4 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,179 Underlying: Series A Common Stock · 3,179 shares Expires 2024-03-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,179 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 3 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,179 shares Expires 2024-03-12 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 5,630 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 2 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,630 Underlying: Series A Common Stock · 5,630 shares Expires 2023-09-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:17 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,630 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001104659-23-082726 · tm2321276-16_4seq1.xml · derivative · entry 1 Kemble George · CIK 0001858176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,630 shares Expires 2023-09-26 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: This option is fully vested and exercisable as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.